Kadcyla 160 mg Injection (Trastuzumab Emtansine) — Targeted Anticancer Therapy for HER2-Positive Breast Cancer Kadcyla 160 mg Injection is a HER2-targeted antibody-drug conjugate containing trastuzumab emtansine, designed to deliver potent chemotherapy directly into cancer cells that overexpress the HER2 protein. Approved for the treatment of HER2-positive breast cancer in adults who have previously received trastuzumab and taxane-based therapy, Kadcyla helps slow tumor progression and improve outcomes. Administered via intravenous infusion by pediatric and adult oncology teams in a clinical setting, this advanced therapy requires regular cardiac, liver, and blood monitoring to manage potential risks like cardiac effects, cytopenias, and hepatotoxicity. Kadcyla 160 mg is available at leading Pakistani oncology pharmacies and medical supply stores with prescription support — available in single-vial formats with nationwide delivery and oncology care support. Always follow your oncologist’s treatment plan and monitoring schedule for optimal safety and effectiveness.